Clinical status and research progress of primary pulmonary mucinous adenocarcinoma
10.3760/cma.j.cn101721-20230430-000161
- VernacularTitle:原发性肺黏液腺癌的临床现状及研究进展
- Author:
Qinghao LIU
1
;
Shijie ZHANG
Author Information
1. 北京大学第一医院胸外科，北京 100034
- Keywords:
Pulmonary mucinous adenocarcinoma;
Clinical features;
Surgery;
Targeted therapy
- From:
Clinical Medicine of China
2023;39(4):261-265
- CountryChina
- Language:Chinese
-
Abstract:
Primary pulmonary mucinous adenocarcinoma is a subtype of lung adenocarcinoma, and its epidemiology is similar to other pulmonary adenocarcinoma. Because of its low incidence rate, the survival data of patients with pulmonary mucinous adenocarcinoma are few and often contradictory. KRAS mutations often occur in pulmonary mucinous adenocarcinoma, but EGFR mutations are rare. The expression of PD-L1 in pulmonary mucinous adenocarcinoma is very low. Patients with early pulmonary mucinous adenocarcinoma can benefit from surgery. Lobectomy is still the standard operation at present, but sub lobectomy may also be effective for early pulmonary mucinous adenocarcinoma. Other treatment options include platinum based dual drug chemotherapy, targeted therapy targeting driving genes, and the recent rise of immunotherapy. Future new targets and corresponding treatments should require more research to confirm.
